Literature DB >> 22867869

Central TSC2 missense mutations are associated with a reduced risk of infantile spasms.

Agnies M van Eeghen1, Mark Nellist, Elmer E van Eeghen, Elizabeth A Thiele.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant syndrome with a variable neurocognitive phenotype. Recently, different intelligence profiles were observed for distinct mutation types and locations, suggesting that individuals with missense mutations represent a subgroup with milder neurocognitive outcomes. We applied these recent insights to the analysis of the epilepsy phenotype in a large cohort of patients with TSC. Associations between genotype and a history of epilepsy and/or infantile spasms (IS) were explored retrospectively, using data from 478 TSC patients from the databases of the Tuberous Sclerosis Alliance and the Herscot Center at Massachusetts General Hospital. Absolute and relative risks for IS and other types of epilepsy were calculated for various mutation classes, selected according to type and location. As expected, TSC2 mutations were associated with a significantly higher occurrence of IS and other epilepsy types. However, missense mutations located in the central region of TSC2 (exons 23-33) were associated with a significantly reduced incidence of IS. Our study further delineates the epilepsy phenotype in TSC patients. Identifying distinct epilepsy phenotypes for specific mutation subgroups may help identify relevant biomarkers and assist clinicians in making treatment decisions.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22867869     DOI: 10.1016/j.eplepsyres.2012.07.007

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  7 in total

1.  Clinical utility gene card for: tuberous sclerosis complex (TSC1, TSC2).

Authors:  Karin Mayer; Christa Fonatsch; Katharina Wimmer; Ans M W van den Ouweland; Anneke J A Maat-Kievit
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

2.  Tuberous Sclerosis Complex Genotypes and Developmental Phenotype.

Authors:  Laura S Farach; Deborah A Pearson; John P Woodhouse; Jeremy M Schraw; Mustafa Sahin; Darcy A Krueger; Joyce Y Wu; Elizabeth M Bebin; Philip J Lupo; Kit Sing Au; Hope Northrup
Journal:  Pediatr Neurol       Date:  2019-03-13       Impact factor: 3.372

3.  Genetic analysis of 18 families with tuberous sclerosis complex.

Authors:  Kaili Yin; Nan Lin; Qiang Lu; Liri Jin; Yan Huang; Xiangqin Zhou; Kaifeng Xu; Qing Liu; Xue Zhang
Journal:  Neurogenetics       Date:  2022-05-21       Impact factor: 3.017

4.  Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models.

Authors:  Laura Magri; Manuela Cominelli; Marco Cambiaghi; Marco Cursi; Letizia Leocani; Fabio Minicucci; Pietro Luigi Poliani; Rossella Galli
Journal:  Dis Model Mech       Date:  2013-06-05       Impact factor: 5.758

5.  TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review.

Authors:  Clévia Rosset; Cristina Brinckmann Oliveira Netto; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2017-02-20       Impact factor: 1.771

6.  Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis.

Authors:  Clévia Rosset; Filippo Vairo; Isabel Cristina Bandeira; Rudinei Luis Correia; Fernanda Veiga de Goes; Raquel Tavares Boy da Silva; Larissa Souza Mario Bueno; Mireille Caroline Silva de Miranda Gomes; Henrique de Campos Reis Galvão; João I C F Neri; Maria Isabel Achatz; Cristina Brinckmann Oliveira Netto; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

7.  Electro-clinical and neurodevelopmental outcome in six children with early diagnosis of tuberous sclerosis complex and role of the genetic background.

Authors:  M N Savini; A Mingarelli; A Peron; F La Briola; F Cervi; R M Alfano; M P Canevini; A Vignoli
Journal:  Ital J Pediatr       Date:  2020-03-27       Impact factor: 2.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.